<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Erlotinib</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00530</strong>&#160; (APRD00951)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Erlotinib hydrochloride (trade name Tarceva, Genentech/<span class="caps">OSIP</span>, originally coded as <span class="caps">OSI</span>-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.</p>
<p>Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (<span class="caps">EGFR</span>) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (<span class="caps">ATP</span>) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00530/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00530/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00530.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00530.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00530.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00530.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00530.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00530">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>OSI-774</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Erlotinib Hydrochloride</strong>
          <div class="cas">183319-69-9</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000064/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000064/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: GTTBEUCJPZQMDZ-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 429.145533978</li>
              <li>Average Mass: 429.897</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000064">DBSALT000064</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Tarceva</td><td>Genetech</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/protein-kinase-inhibitors">Protein Kinase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>183321-74-6</td></tr><tr><th>Weight</th><td>Average: 393.4357<br>Monoisotopic: 393.168856239</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>AAKJLRGGTJKAMG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COCCOC1=C(OCCOC)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthyridines</td></tr><tr><th>Subclass</th><td>Quinazolines</td></tr><tr><th>Direct parent</th><td>Quinazolinamines</td></tr><tr><th>Alternative parents</th><td>Phenol Ethers; Alkyl Aryl Ethers; Aminopyrimidines and Derivatives; Polyamines; Secondary Amines</td></tr><tr><th>Substituents</th><td>phenol ether; aminopyrimidine; alkyl aryl ether; benzene; pyrimidine; polyamine; secondary amine; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.</td></tr><tr><th>Pharmacodynamics</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Mechanism of action</th><td>The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.</td></tr><tr><th>Absorption</th><td>Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH dependent. Solubility decreases pH increases. Smoking also decrease the exposure of erlotinib. </td></tr><tr><th>Volume of distribution</th><td><p>Apparent volume of distribution = 232 L</p></td></tr><tr><th>Protein binding</th><td>93% protein bound to albumin and alpha-1 acid glycoprotein (AAG)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolism occurs in the liver. In vitro assays of cytochrome P450 metabolism showed that erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1.</p></td></tr><tr><th>Route of elimination</th><td>Following a 100 mg oral dose, 91% of the dose was recovered in which 83% was in feces (1% of the dose as unchanged parent compound) and 8% in urine (0.3% of the dose as unchanged parent compound). </td></tr><tr><th>Half life</th><td>Median half-life of 36.2 hours.</td></tr><tr><th>Clearance</th><td><p>Smokers have a 24% higher rate of erlotinib clearance.</p></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include diarrhea, rash, and liver transaminase elevation. The most common adverse reactions (&gt;50%) in NSCLC are rash, diarrhea, anorexia and fatigue. The most common adverse reactions (&gt;50%) in pancreatic cancer are fatigue, rash, nausea and anorexia. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Erlotinib Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Epidermal growth factor receptor<br>Gene symbol: EGFR<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P00533" target="_blank">P00533 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G719A/C OR (L858R and L861Q)</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Associated with enhanced activation of the EGFR tyrosine kinase in patients with non-small cell lung cancer (NSCLC) recieving  tyrosine kinase inhibitor therapy.</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15118073" target="_blank" title='# Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15118073'>15118073 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9359</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9376</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5737</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5982</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5958</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6169</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7171</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7942</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7611</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5886</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.7826</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5739</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6329</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.598</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7194</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7911</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.5195
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9551
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9907
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3958 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8158
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6776
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Osi pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.gene.com">Genentech Inc.</a></li>
<li><a href="http://www.osip.com">OSI Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Schwarz Pharma Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>25 mg, 100 mg, 150 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may decrease the metabolism of erlotinib. Monitor for changes in the therapeutic and adverse effects of erlotinib if itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Decreased levels/effect of erlotinib</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Decreased levels/effect of erlotinib</td></tr><tr><td><a href="/drugs/DB01201">Rifapentine</a></td><td>Decreased levels/effect of erlotinib</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Decreased levels/effect of erlotinib</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Erlotinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erlotinib if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erlotinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of erlotinib if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take at least 1 hour before or 2 hours after any food.</li>
<li>Take with a glass of water.</li></ul></td></tr></tbody></table>